Current Assets
Cash & Equivalents
Roivant Sciences Cash & Equivalents increased by 1443.7% to $1.42B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1410.6%, from $93.95M to $1.42B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows a downward trend with a -7.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ4 2013
Last reportedQ1 2026
How to read this metric
Higher levels indicate strong liquidity and financial flexibility; lower levels may signal potential cash flow issues.
Detailed definition
This represents the most liquid assets held by the company, including cash on hand, demand deposits, and short-term inve...
Peer comparison
A universal metric for assessing a company's immediate financial health.
Metric ID:
cash_and_equivalentsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.01B | $2.51B | $2.23B | $2.07B | $1.96B | $1.61B | $1.54B | $1.69B | $1.45B | $1.42B | $6.69B | $182.67M | $5.69B | $123.48M | $99.08M | $93.95M | $94.79M | $102.19M | $91.94M | $1.42B |
| QoQ Change | — | +24.9% | -11.3% | -6.8% | -5.7% | -17.6% | -4.4% | +9.8% | -14.3% | -1.8% | +369.8% | -97.3% | >999% | -97.8% | -19.8% | -5.2% | +0.9% | +7.8% | -10.0% | >999% |
| YoY Change | — | — | — | — | -2.6% | -35.7% | -30.8% | -18.4% | -25.9% | -11.7% | +333.8% | -89.2% | +292.7% | -91.3% | -98.5% | -48.6% | -98.3% | -17.2% | -7.2% | >999% |
Range$91.94M – $6.69B
CAGR-7.0%
Avg YoY Growth+91.3%
Median YoY Growth-22.2%
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Roivant Sciences's cash & equivalents?
- Roivant Sciences (ROIV) reported cash & equivalents of $1.42B in Q1 2026.
- How has Roivant Sciences's cash & equivalents changed year-over-year?
- Roivant Sciences's cash & equivalents increased by 1410.6% year-over-year, from $93.95M to $1.42B.
- What is the long-term trend for Roivant Sciences's cash & equivalents?
- Over 5 years (2020 to 2025), Roivant Sciences's cash & equivalents has grown at a -7.9% compound annual growth rate (CAGR), from $2.14B to $1.42B.
- What does cash & equivalents mean?
- Cash and highly liquid assets that can be converted to cash within 90 days.